Ward, Kar, Balan, and Bhardwaj @BhardwajLab review how conventional type 1 #DendriticCells (cDC1s) coordinate antitumor immunity through cross-presentation, immune cell networking, and spatial organization in tumors. https://t.co/A77oF770ZS
#CancerFocus#Immunotherapy
Excited to share out latest work, out this week in @NatureGenet . In this study, we using CRISPR screens to explore how sensing inflammatory cytokines exposes new tumor-intrinsic dependencies.
@broadinstitute@MGBResearchNews
https://t.co/GDeVFJUDcn
The concept of oligometastatic disease has reshaped the management paradigm for many solid tumours because some patients may achieve long-term disease control or even cure with aggressive local therapy. https://t.co/ZcVhOeq7dP
#Myeloid diversity in tumors: shaped by genes, location, and time. Review by Maria Nogales-Pons, Mariola Munárriz-Paños, Teresa Aceña-Gonzalo, & María Casanova-Acebes @Casanova_Acebes: https://t.co/jjWBCjZ9UX
📘 Part of JEM #Cancer Collection: https://t.co/YPWs2KQyqx
#EACR2026
Next generation sequencing of circulating tumor DNA for precision medicine in patients with advanced biliary tract cancers | Clinical Cancer Research | American Association for Cancer Research https://t.co/50Rpuv5zHu
🚨 Is tumor type really the best predictor of long-term benefit from immunotherapy?
Maybe not.
In a nationwide cohort of 2,127 responders to PD-1/PD-L1 blockade across melanoma, RCC, and NSCLC:
✅ Complete responders (CR) had dramatically better outcomes than partial responders (PR)
✅ Response depth was the strongest predictor of progression risk
✅ Tumor type added surprisingly little prognostic information once response depth was known
📊 5-year PFS:
🔹 Melanoma
CR 74% vs PR 19%
🔹 RCC
CR 68% vs PR 24%
🔹 NSCLC
CR 67% vs PR 19%
After propensity-score matching, PFS curves were nearly superimposable across tumor types.
💡 The implication:
For patients who respond to PD-1/PD-L1 blockade, how deep the response is may matter more than where the cancer started.
This raises an important question:
Should future immunotherapy trials focus less on tumor-specific surveillance and more on strategies that convert PR → CR?
🔖 Worth saving for anyone interested in immunotherapy durability and acquired resistance.
📖 Full paper in comment ⬇️
#OncoTwitter #MedTwitter #Immunotherapy #Melanoma
@OncoAlert@myesmo@esmo_open@ASCO
The NHS-Galleri trial reportedly failed its primary endpoint—a sobering reminder from @SullivanProf
and Dr Christopher Booth in this editorial at @JAMA_current
that technological elegance is no substitute for proven patient benefit. 🙂👇 @oncology_bg
https://t.co/SBy5n16VQf
🆕@JCOPO_ASCO
💡Such a beautiful story of real world🌎 precision medicine.
Meet➡️#ERRFI1🎯
📝Time to add➕this to ACTIONABLE Biomarkers🔐for #cholanagiocarcinoma@curecc. @NCCN
👇🏽Patient in paper, I took off hospice to give Erlotinib💊.
@OncoAlert
🔗https://t.co/09PD5QHv0s
Detecting lung cancer 5 years before it happens, in @CellCellPress courtesy of the @CharlesSwanton group.
Astonishing translational work !
https://t.co/EvUmIGVLgs
A holy grail for our lab has been tracking myeloid cells in human tumors in the same way that we track T and B cells with TCR/BCR.
@vincentzliu and @CalebLareau solved it!
We developed Mitotrek using scATAC-seq + mitochondrial DNA to do exactly this. Using Mitotrek, we find that new myeloid cells clones constantly infiltrate the tumor via circulating monocytes — and that their macrophage or dendritic cell fate is epigenetically programmed before tumor entry.
@10xGenomics@parkerici@CancerResearch@TheMarkFdn
https://t.co/Y37qbyw3F5
i know the White House thinks it's cute that nobody in the administration has real responsibilities beyond fluffing the president on TV, but that disaster of a press briefing by Dr Oz is a reminder that it's actually good to know what you're talking about
A new Science #Immunology Review delves into the transcriptional and #epigenetic regulatory mechanisms that shape #macrophage identity and function in health and disease. https://t.co/MYOZv9Edxy
🚨 Our pre-proof is out on @Annals_Oncology!
BRIDGE, a framework to quantify intratumoral subtype mixtures in #BreastCancer and predict neoadjuvant response, including directly from H&E slides
Paper: https://t.co/VxSklz9oVH
🧵1/11
1/ Thrilled to share our new paper, out today in @ScienceMagazine! We built a pan-cancer spatial atlas of tertiary lymphoid structures (TLSs) and developed computation and AI frameworks to study TLS biology at scale.
https://t.co/zgcBnnm7Rl